Good morning, welcome to the 2026 annual meeting of stockholders of Kyntra Bio, Inc. I would now like to turn the call over to Thane Wettig, the CEO and director of Kyntra Bio. Please go ahead.
Thank you, good morning. I am pleased to welcome everyone to the Kyntra Bio 2026 annual meeting of stockholders. At the request of the chairperson of our board, Jim Schoeneck, I will act as chairman of this meeting. Joining us today are members of the board, Jim Schoeneck, chairman of the board, Jeffrey Edwards, and Dr. Maykin Ho. Please let me also introduce John Alden, our general counsel, who will act as secretary and inspector of elections of this meeting. Finally, Jitin Kalra of PricewaterhouseCoopers, Kyntra's auditor, is also available to respond to relevant questions. Before turning to the formal business of the meeting, I would like John to go over a few procedural matters.
Thank you, Thane, good morning, everyone. Stockholders of Kyntra Bio as of April 16th, 2026 record date, are able to vote during the meeting until we close the polls following the presentation of the proposals. If a stockholder has already voted online, by telephone, or by mail, voting at this meeting is not necessary. However, a vote submitted at this meeting will supersede any earlier vote. Questions pertaining to the business of this meeting may be submitted by stockholders during the meeting by clicking on the Q&A button in the bottom left portion of the website for this meeting. If we do not get to your question, you are welcome to send it to ir@kyntrabio.com. Finally, we are recording this meeting and you will be able to replay the recording for 30 days. Please wait a day or so after this meeting for the recording to be uploaded.
It will be uploaded to this annual meeting site. The time is now 8:02 A.M. Pacific Time on Friday, June 12th, 2026, the meeting will officially come to order. Thane?
Yes. Will the secretary please report on the stockholders list and mailing of the notice of the meeting?
A complete list of Kyntra Bio's stockholders as of April 16th, 2026, the record date for this meeting, is available on the virtual meeting website. I also have with me an affidavit certifying that commencing on April 27th, 2026, a notice of annual meeting of stockholders was sent to all such stockholders of record.
Mr. Alden has been appointed by the board to act as Inspector of Elections at this meeting and has taken and subscribed the customary oath of office to execute his duties with strict impartiality, which will be filed with the records of the meeting. His function is to decide upon the qualifications of voters, accept their votes, and to tally the final votes. Will the secretary please report at this time with respect to the existence of a quorum?
Proxies have been received for 2,734,678 of the 4,048,112 shares of common stock outstanding on the record date, which represents approximately 67.55% of the total number of outstanding shares. This constitutes a quorum today, we may now carry out the official business of the meeting.
There are three proposals to be considered by the stockholders at this meeting. The first item of business today is the election of our Class III director nominee, Dr. Michael Kauffman, to the board to hold office until the 2029 annual meeting of stockholders or until his successor is elected. The second item of business today is the approval on an advisory basis of the compensation of Kyntra Bio's named executive officers as disclosed in Kyntra's 2026 proxy statement filed on April 27th, 2026. The third and final item of business today is the ratification of the selection of PricewaterhouseCoopers LLP by the Audit Committee of the Board of Directors as the independent registered public accounting firm of Kyntra Bio for the year ending December 31st, 2026. John?
Apologies. I was on mute. Thanks, Thane. Since there were no questions, we will now describe the voting procedures. Each share of common stock is entitled to one vote. Voting is by proxy, telephone, and mail prior to the annual meeting. By proxy online at www.virtualshareholdermeeting.com/kynb2026 during the annual meeting. You do not need to vote on the stockholder meeting website if you have already voted your proxy online, by telephone, or by mail. The time is now 8:05 A.M. Pacific Time, the polls are now closed for voting.
May we have the results of the voting?
My report as Inspector of Elections covering the proposals presented at this meeting is as follows. The first proposal to elect our Class III director nominee, Dr. Michael Kauffman, to the board is carried with the holders of 96.04% of the shares voting in favor of the proposal. The second proposal to approve on an advisory basis the compensation of Kyntra Bio's named executive officers, as disclosed in Kyntra's 2026 proxy statement, has passed with 1,242,005 shares voting in favor, 23,606 shares opposed, 24,639 shares abstaining. The third proposal, the selection of PricewaterhouseCoopers LLP by the Audit Committee of the Board of Directors as the independent registered public accounting firm of Kyntra Bio for the year ending December 31st, 2026, has been ratified with 2,712,825 shares voting in favor 14,392 shares opposed.
We expect to report our final voting results on a current report on Form 8-K with the SEC within four business days after the end of this meeting.
Thank you, John. This concludes today's business and the meeting is now adjourned. Thank you all for attending the Kyntra Bio 2026 annual stockholders meeting. Have a nice day.
Ladies and gentlemen, this concludes today's annual meeting. You may now disconnect.